According to TipRanks.com, Schwartz is ranked #4411 out of 4875 analysts.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $117.80, implying a 37.6% upside from current levels. In a report issued on September 4, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $124 price target.
Based on AnaptysBio Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.62 million. In comparison, last year the company earned revenue of $7 million and had a GAAP net loss of $2.68 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANAB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.